Multiple Technology Appraisals (MTAs)

MTAs evaluate multiple drugs in the same indication. In MTAs, SCHARR-TAG systematically reviews, synthesises the clinical evidence, and constructs its own mathematical model providing estimates of cost-effectiveness to the NICE appraisal committee.

Off

2023 | 2021 | 2020 | 2019 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

2023

Baricitinib, casirivimab/imdevimab, lenzilumab, molnupiravir, nirmatrelvir/ritonavir, remdesivir, sotrovimab, and tocilizumab, for the treatment of COVID-19 [ID4038].

2021

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375, NIHR Ref: 11/74/01) [ID2710].

2020

Non Bisphosphonates for Osteoporosis. Review of (TA160, TA161, TA204) [ID901].

2019

Cabozanitinib and vandatinib for advanced or metastatic medullary thyroid cancer [ID56].

2017

Dexamethasone intravitreal implant and sirolimus for treating chronic non-infectious posterior segment uveitis [ID763].

2016

Bisphosphonates for preventing osteoporotic fragility fractures [ID782].

Adalimumab, etanercept, infliximab, certolizumab pegol and golimumab for the treatment of rheumatoid arthritis. Review of TA130, TA186 and TA225 [ID537].

Infliximab, adalimumab and golimumab for the treatment of second-line sub-acute manifestations of ulcerative colitis [TA329] (12/51/01).

2014

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis [TA279] (10/122/01).

2013

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model [TA276] (10/08/01).

2012

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation (09/141/01).

2011

A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (PAD) (09/92/01).

2010

Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation (08/227/01).

2009

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation (07/08/01).

Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation (07/35/01).

Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation (07/05/01).

Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis (06/66/01).

2008

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation (05/22/01).

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation (04/12/01).

2007

Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation (06/18/01).

Hormonal therapies for early breast cancer: systematic review and economic evaluation (03/20/01).

A systematic review and economic evaluation of statins for the prevention of coronary events (03/30/01).

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (04/46/01).

The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women (04/28/01).

2006

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation (04/18/01).

Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation (04/01/01).

Parent-training/education programmes in the management of children with conduct disorders (TA 102).

2005

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis (01/58/01).

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies (01/48/01).

2004

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine (01/49/01).

Rituximab (MabThera®) for aggressive non-Hodgkin’s lymphoma: systematic review and economic evaluation (02/17/01).

Methods for the expected value of information analysis in complex health economic models: developments on the health economics of interferon- and glatiramer acetate for multiple sclerosis (02/29/01).

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis (02/27/01).

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation (01/54/01).

Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review (01/31/01).

A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography (02/43/01).

2003

Treatments for spasticity and pain in multiple sclerosis: a systematic review (99/05/03).

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review (01/36/01).

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation (01/56/01).

The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heartbeating and non-heart-beating donors (01/35/01).

The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation (01/24/01).

A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative (00/23/01).

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA 64).

The management of inhibitors in haemophilia A: Introduction and systematic review of current practice (RCD01960). Haemophilia. 2003; Volume 9 Issue 4, Pages 405 – 417.

2002

A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety (01/23/01).

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models (99/05/02).

The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation (00/22/01).

2001

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (00/13/01).

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer (00/10/01).

The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review (00/06/01).

2000

Liquid-based cytology in cervical screening: a rapid and systematic review (99/18/01).

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA 10)